| Tipoffs for Maine (New England) Newsletter for Monday June 05, 2023 ( 6 items ) |
|
American Society of Clinical Oncology: Radiation Can Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer
ALEXANDRIA, Virginia, June 5 (TNSjou) -- The American Society of Clinical Oncology issued the following news release:
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery based on the findings of federally funded research that will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in the New England Journal of Medicine (efficacy) and the Jour
more
ASCO 2023: New Research From Memorial Sloan Kettering Cancer Center and Dana-Farber Brigham Cancer Center Finds That Radiation Can Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer
NEW YORK, June 5 (TNSjou) -- The Memorial Sloan Kettering Cancer Center issued the following news release on June 4, 2023:
New data led by researchers at Memorial Sloan Kettering Cancer Center (MSK) and Dana-Farber Brigham Cancer Center featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in The New England Journal of Medicine (NEJM) and the Journal of Clinical Oncology today indicates that some patients with locally advance
more
ASCO 2023: New Research From Memorial Sloan Kettering Cancer Center Identifies Significant Treatment Advancement for Brain Tumors
NEW YORK, June 5 (TNSjou) -- The Memorial Sloan Kettering Cancer Center issued the following news release on June 4, 2023:
Breakthrough data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in The New England Journal of Medicine (NEJM) today found that vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free surv
more
Dana-Farber Brigham Cancer Center, Memorial Sloan Kettering Cancer Center Find Radiation Can Be Safely Omitted in Patients With Advanced Rectal Cancer
BOSTON, Massachusetts, June 5 (TNSjou) -- The Dana-Farber Cancer Institute issued the following news release on June 4, 2023:
New data led by researchers at Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center (MSK) and featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in The New England Journal of Medicine (NEJM) and the Journal of Clinical Oncology today indicates that some patients with locally
more
Dana-Farber Cancer Institute: Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades
BOSTON, Massachusetts, June 5 (TNSres) -- The Dana-Farber Cancer Institute issued the following news release on June 4, 2023:
* * *
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.
* * *
In a global phase 3, double-blinded, randomized clinical trial, a precision therapy called vorasidenib more than doubled progression-fr
more
University of Maryland School of Medicine: Multiple Sclerosis More Prevalent in Black Americans Than Previously Thought
BALTIMORE, Maryland, June 3 (TNSjou) -- The University of Maryland School of Medicine issued the following news:
* * *
UM School of Medicine Researchers Also Find Disease More Prevalent in Northern Parts of the U.S.
* * *
Multiple sclerosis has traditionally been considered a condition that predominantly affects white people of European ancestry. However, a new analysis conducted by a North American team led by University of Maryland School of Medicine (UMSOM) researchers suggests that the d
more
|
Sign up to Receive this newsletter every day via email.